Author

G. Heller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell-cell communication· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2

Frequent Co-Authors

A. Di Ruscio· 2 shared A. K. Ebralidze· 2 shared A. Quintanal-Villalonga· 2 shared B. Q. Trinh· 2 shared C. M. Rudin· 2 shared D. G. Tenen· 2 shared E. de Stanchina· 2 shared E. van der Kouwe· 2 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Di Ruscio

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Melanoma cells release DEL-1 via small extracellular vesicles

M. Schnödl, F. Tuchmann, J. Wenzina, k. Neumüller, G. Mitulovic, M. Groeger, G. Heller, P. Petzelbauer

The paper shows melanoma cells release DEL-1 via small extracellular vesicles and demonstrates the potential of sEV proteomics to predict treatment responses in melanoma patients.

bioRxiv · Apr 4, 2022 · PreprintCancer Biology

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

A. Chow, F. Z. Uddin, L. Mangarin, H. Rizvi, A. Dobrin, S. E. Tischfield, A. Quintanal-Villalonga, J. M. Chan, N. S. Shah, V. Allaj, P. Manoj, M. Mattar, M. Meneses, M. Liu, R. Landau, , C. M. Rudin

This study identifies CD39 as a marker for tumor-reactive CD8 T cells in lung cancer, showing its association with clinical outcomes and response to immune checkpoint therapy.

bioRxiv · Jan 24, 2022 · PreprintImmunology

A cutting-edge approach unravels a novel role for CDK6 in leukemic progenitor cells

E. Doma, I. M. Mayer, T. Brandstoetter, B. Maurer, R. Grausenburger, I. Menzl, M. Zojer, A. Hoelbl-Kovacic, L. Carlsson, G. Heller, K. Kollmann, V. Sexl

This paper introduces a method to generate HPCLSK cells that mimic hematopoietic/leukemic progenitor cells and shows CDK6's role in leukemia formation and homing.

bioRxiv · Oct 5, 2020 · PreprintCancer Biology

Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML

B. Q. Trinh, S. Ummarino, A. K. Ebralidze, E. van der Kouwe, M. A. Bassal, T. M. Nguyen, R. Coffey, D. E. Tenen, E. Fabiani, C. Gurnari, C.-S. Wu, V. E. Angarica, Y. Zhang, L. Ying, H. Yang, , D. G. Tenen

The paper identifies the long noncoding RNA LOUP as a mediator of RUNX1 and RUNX1-ETO effects in t(8;21) AML, showing it promotes myeloid differentiation and inhibits cell growth by regulating PU.1 expression.

bioRxiv · Jul 24, 2020Cancer Biology

Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter

E. van der Kouwe, G. Heller, A. Czibere, L. H. Castilla, R. Delwel, A. Di Ruscio, A. K. Ebralidze, M. Forte, L. Kazianka, C. Kornauth, T. Le, K. Lind, I. A. Monteiro Barbosa, A. Pichler, J. A. Pulikkan, , P. B. Staber

The paper shows that CBF fusions in AML activate the PU.1 antisense promoter, reducing sense PU.1 transcription and blocking myeloid differentiation, similar to T-cell differentiation.

bioRxiv · May 29, 2020Cancer Biology

Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics

C. H. Hulton, E. A. Costa, N. S. Shah, A. Quintanal-Villalonga, G. Heller, E. de Stanchina, C. M. Rudin, J. T. Poirier

This study develops a CRISPR-Cas9 lentiviral platform for genome editing of patient-derived xenografts to analyze genetic dependencies and drug resistance mechanisms in vivo.

bioRxiv · Mar 26, 2019Cancer Biology